SeaStar Medical Holding Stock Price, News & Analysis

SeaStar Medical Holding Corporation (Nasdaq: ICU) is a commercial-stage healthcare and medical technology company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. According to company disclosures, SeaStar Medical develops and commercializes therapies based on its patented Selective Cytopheretic Device (SCD) technology, which is designed to address destructive hyperinflammation that can shut down organ function and increase the risk of death in conditions such as acute kidney injury (AKI).

SeaStar Medical operates through a single reportable Device Segment, as described in its corporate materials. The company’s first commercial product is QUELIMMUNE (SCD-PED), a therapy based on SCD technology. QUELIMMUNE is being commercialized for critically ill pediatric patients (age 22 or younger) with life-threatening AKI due to sepsis or a septic condition who are on antibiotics and receiving Renal Replacement Therapy (RRT) in the intensive care unit. The therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE).

Company press releases state that QUELIMMUNE is the only FDA approved product for the ultra-rare condition of life-threatening AKI due to sepsis or a septic condition in critically ill pediatric patients. Medical institutions that adopt QUELIMMUNE are required to participate in the SAVE Surveillance Registry, a post-approval Real-World Evidence program designed to confirm the safety of the therapy. Institutions must also complete Institutional Review Board approvals prior to adoption and use, which SeaStar Medical notes can prolong the adoption timeline but provides important real-world data.

SeaStar Medical’s SCD therapy is described as a disease-modifying device intended to neutralize over-active immune cells and interrupt the cytokine storm that drives destructive hyperinflammation. Company materials explain that, unlike pathogen removal or other blood-purification tools, the SCD therapy is integrated with existing continuous renal replacement therapy (CRRT) hemofiltration systems. It is designed to selectively target and transition proinflammatory monocytes to a reparative state and to promote activated neutrophils to be less inflammatory. This immunomodulation approach is intended to support long-term organ recovery, reduce the need for future renal replacement therapies such as dialysis, and reduce loss of life.

Clinical and real-world data cited by SeaStar Medical highlight the potential impact of QUELIMMUNE in pediatric AKI. Data from two clinical studies published in Kidney Medicine showed a 77% survival rate in patients treated with QUELIMMUNE compared with standard of care, which the company describes as an approximate 50% reduction in loss of life compared to historical data in this patient population. Among survivors, no dialysis was required, and 87.5% had normal kidney function at Day 60 after ICU discharge. Preliminary data from the SAVE Surveillance Registry in commercial use have shown zero device-related safety events and survival rates that the company reports are on track to validate a substantial reduction in loss of life compared to historical outcomes.

SeaStar Medical also emphasizes the broader applicability of its SCD therapy beyond pediatric AKI. Company communications describe ongoing development programs in adult AKI and in cardiovascular indications. The NEUTRALIZE-AKI pivotal trial is evaluating the safety and efficacy of SCD therapy in adults with AKI in the ICU receiving CRRT. This randomized clinical trial uses a primary endpoint of a composite of 90-day mortality or dialysis dependency, comparing patients treated with SCD plus CRRT to those receiving CRRT alone as standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90, and dialysis dependency at one year. Subgroup analyses are planned to explore effectiveness in AKI patients with sepsis and acute respiratory distress syndrome.

An independent Data Safety Monitoring Review Board (DSMB) has reviewed interim data from the NEUTRALIZE-AKI trial and, according to an 8-K filing and related press release, reported zero device-related safety issues and a signal of potential clinical benefit in the treatment group. Based on this analysis and the trial’s statistical plan, the DSMB recommended increasing total enrollment to approximately 339 patients to strengthen statistical power, and recommended continuation of the trial.

SeaStar Medical reports that its SCD therapy has been awarded FDA Breakthrough Device Designation for six therapeutic indications. For the adult AKI indication requiring CRRT and for patients with acute chronic systolic heart failure with cardiorenal syndrome (CRS) awaiting left ventricular assist device (LVAD) implantation, the company notes that Breakthrough Device Designation is intended to expedite the Premarket Approval (PMA) process for novel devices that may save lives or treat debilitating diseases. The company is also evaluating SCD therapy in patients with severe heart failure and has initiated the NEUTRALIZE-CRS clinical trial in patients with acute CHF with CRS awaiting LVAD implantation.

SeaStar Medical’s public communications describe AKI as a sudden and temporary loss of kidney function that can result from sepsis, severe trauma, surgery, or COVID-19. The company explains that AKI can trigger destructive hyperinflammation, with overproduction or overactivity of inflammatory effector cells and molecules that can damage organs beyond the kidney, including the heart and liver, and can lead to multi-organ dysfunction or failure. Even after apparent resolution, patients may face chronic kidney disease or end-stage renal disease requiring dialysis, and hyperinflammation can contribute to prolonged ICU stays and increased use of dialysis and mechanical ventilation.

In recognition of its work in pediatric AKI, SeaStar Medical reports that it received the 2025 Corporate Innovator Award from the National Kidney Foundation for its contribution to improving the lives of pediatric patients with AKI based on the approval and introduction of QUELIMMUNE therapy. The company also notes that QUELIMMUNE has been adopted by nationally recognized and top-rated children’s medical centers in the United States, and that these institutions are contributing data to the SAVE Surveillance Registry.

SeaStar Medical’s common stock trades on the Nasdaq Capital Market under the symbol ICU, and its warrants trade under the symbol ICUCW, as disclosed in SEC filings. The company has undertaken corporate actions such as a 1-for-10 reverse stock split approved by stockholders at a special meeting and implemented to help the company regain compliance with Nasdaq listing requirements related to minimum bid price. SEC filings detail that the reverse split affected issued and outstanding common shares and proportionally adjusted outstanding stock options and certain warrants, without changing the rights or preferences of the common stock.

Overall, SeaStar Medical positions itself as a commercial-stage medical technology and healthcare company centered on SCD-based extracorporeal therapies aimed at modifying the immune response in hyperinflammatory conditions. Its business is currently anchored by the QUELIMMUNE pediatric AKI indication under HDE approval, with ongoing pivotal and exploratory trials intended to expand the potential use of SCD therapy in adult AKI and in cardiovascular settings where organ failure risk is high and effective disease-modifying treatments are limited, according to the company’s own descriptions.